Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

DURECT Corporation (DRRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.1600-0.0100 (-0.85%)
At close: 4:00PM EDT
1.1500 -0.01 (-0.86%)
After hours: 05:19PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.1700
Open1.1400
Bid1.1600 x 28000
Ask1.1900 x 3200
Day's Range1.1200 - 1.1853
52 Week Range1.1000 - 2.9500
Volume717,650
Avg. Volume456,750
Market Cap263.895M
Beta (5Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)-0.1180
Earnings DateNov 01, 2021 - Nov 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DRRX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • DURECT Corporation
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total sales are generated in the United States.
    Rating
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
  • PR Newswire

    DURECT Corporation Fireside Chat at the H.C. Wainwright 5th Annual NASH Investor Conference

    DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Ed Arce, Managing Director of Equity Research at H.C. Wainwright.

  • PR Newswire

    DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2021

    DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Kristen Kluska, Director, Equity Research Analyst at Cantor Fitzgerald.

  • PR Newswire

    DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit

    DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc.

Advertisement
Advertisement